Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.45 USD
Change Today +1.57 / 9.89%
Volume 521.4K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

calithera biosciences inc (CALA) Snapshot

Open
$15.87
Previous Close
$15.88
Day High
$18.44
Day Low
$15.00
52 Week High
12/15/14 - $33.48
52 Week Low
10/10/14 - $6.51
Market Cap
313.2M
Average Volume 10 Days
500.0K
EPS TTM
--
Shares Outstanding
17.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CALITHERA BIOSCIENCES INC (CALA)

Related News

No related news articles were found.

calithera biosciences inc (CALA) Related Businessweek News

No Related Businessweek News Found

calithera biosciences inc (CALA) Details

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.

37 Employees
Last Reported Date: 03/27/15
Founded in 2010

calithera biosciences inc (CALA) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $484.8K
Senior Vice President of Research
Total Annual Compensation: $364.1K
Senior Vice President of Drug Discovery
Total Annual Compensation: $364.1K
Compensation as of Fiscal Year 2013.

calithera biosciences inc (CALA) Key Developments

Calithera Biosciences, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Calithera Biosciences, Inc. reported unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $6,838,000 compared to $4,088,000 a year ago. Net loss and comprehensive loss was $6,833,000 compared to $4,087,000 a year ago. For the year, the company reported loss from operations of $21,721,000 compared to $12,378,000 a year ago. Net loss and comprehensive loss was $21,712,000 compared to $12,377,000 a year ago.

Calithera Biosciences, Inc. Announces Resignation of Ralph E. Christoffersen as Board of Directors

On March 19, 2015, Dr. Ralph E. Christoffersen notified Calithera Biosciences, Inc. of his decision not to stand for re-election to Board of Directors when his current term expires at 2015 annual meeting of stockholders. Dr. Christoffersen will continue to serve as a member of Board of Directors until the conclusion of the 2015 annual meeting of stockholders.

Calithera Biosciences, Inc. to Report Q4, 2014 Results on Mar 26, 2015

Calithera Biosciences, Inc. announced that they will report Q4, 2014 results on Mar 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CALA:US $17.45 USD +1.57

CALA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CALA.
View Industry Companies
 

Industry Analysis

CALA

Industry Average

Valuation CALA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CALITHERA BIOSCIENCES INC, please visit www.calithera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.